Effect of empagliflozin on liver fibrosis and steatosis in patients with type 2 diabetes and non-alcoholic fatty liver disease: a randomized clinical trial.

BMC Endocr Disord · 2025 · PMC12664258 · PMID 41316185

Europe PMC DOI

hedged sentences

0.0010

closest p · 0.0× alpha

0.0790

boldest claim

The sentences

highly significantp < 0.001actually significant

The results confirmed the robustness of our findings: liver enzyme reductions (ALT, AST, and GGT) and fasting blood sugar remained highly significant (all p < 0.001), while nonsignificant outcomes such as NFS and platelet counts remained unchanged.

also in 132,142 other papers

did not reach statistical significancep = 0.079so close (0.05 < p ≤ 0.1)

AST levels were also higher in the experimental group, though the difference did not reach statistical significance ( p = 0.079).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.